株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

癌免疫療法の世界市場の予測:養子T細胞療法 - 2022年までの予測

The Global Immuno-oncology Therapeutics Market - Adoptive T-cell Therapies, Forecast to 2022

発行 Frost & Sullivan 商品コード 602455
出版日 ページ情報 英文 123 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=111.31円で換算しております。
Back to Top
癌免疫療法の世界市場の予測:養子T細胞療法 - 2022年までの予測 The Global Immuno-oncology Therapeutics Market - Adoptive T-cell Therapies, Forecast to 2022
出版日: 2018年01月19日 ページ情報: 英文 123 Pages
概要

当レポートでは、世界の癌免疫療法の市場を調査し、市場の定義と概要、養子T細胞療法の概要・開発状況・適応症、CAR-T製品・TCR製品のダッシュボード、商業化における課題と市場機会、償還動向、注目の企業・製品、将来の展望などをまとめています。

第1章 エグゼクティブサマリー

第2章 ディスラプティブパイプライン分析

  • 主な手法
  • 養子T細胞療法の薬剤クラス
  • 養子T細胞製品の発展のタイムライン
  • 癌養子免疫療法製品の承認

第3章 競合環境

  • 競合環境:標的の分類
  • 競合環境:標的製品カウント
  • 養子T細胞療法の分類
  • 競合環境:CAR-T (キメラ抗原受容体T細胞)
  • 競合環境:T細胞受容体 (TCR)

第4章 主な養子T細胞療法製品のダッシュボード

  • CAR-T製品
  • TCR製品

第5章 商業化の分析

  • 市場機会
  • 課題
  • 潜在的ゲームチェンジング癌免疫療法
  • 総合的な影響因子
  • 特許の失効

第6章 商業化の分析:バイオマーカー

  • 標的抗原

第7章 商業化の分析:コストの考察

  • 市場機会
  • 養子T細胞療法:保険者環境
  • Jコード・年間コスト・米国の保険者
  • 養子T細胞療法:オンラベル償還経路
  • オフラベル償還経路:Medicare
  • オフラベル償還経路:民間保険者
  • 世界の薬価統制
  • 回避すべき障壁

第8章 商業化の分析:注目の企業・製品

  • 注目の企業
  • 予測:製品別

第9章 商業化の分析:資金に関する考察

  • マイルストーン
  • 契約・資金調達:養子T細胞療法

第10章 総論・将来の展望

第11章 付録:CAR-T療法の開発パイプラインサマリー

第12章 付録:T細胞受動態療法の開発パイプラインサマリー

第13章 FROST & SULLIVANについて

目次
Product Code: MC55-52

The Next Generation of Cancer Therapies

Immuno-oncology refers to drugs that are used to stimulate the human immune system to target the fight against cancer. The immune system is capable of recognizing and eliminating foreign substances, including tumor cells. Tumors have, however, been able to escape detection by the immune system. There are drugs that can empower the immune system cells to attack tumor cells. Natural Killer (NK) cells are the main cells involved in the natural immune response. Once an immune response is initiated, the immune response can be sustained through memory, called adaptive immunity. Cytotoxic T cells are the main cells involved with adaptive immunity. The anti-cancer activity of NK cells and cytotoxic T cells is done through activating and inhibiting signal pathways.

Chimeric antigen receptor (CAR) T-cell therapy will change the way cancer is being treated. In the second half of 2017, the first two drugs in this new class of therapy were approved. Autologous T-cells that have been re-engineered can resist the immunosuppressive effects of tumors. The approved CAR-T therapies are directed against CD19 antigens and are approved to treat B-cell lymphoma and acute lymphocytic leukemia's, both B-cell mediated diseases. The process involved engineering autologous antigen presenting cells removed from the patient and run through a manufacturing process that takes 17 to 29 days depending on the drug before being infused back into the patient. There are over 200 clinical trials underway with CAR-T therapeutics, some trials in combination with already approved checkpoint inhibitors. The autologous therapies are patient-specific personalized treatments. The costs are staggering for these therapies, with treatments for the drug alone costing hundreds of thousands of dollars. That does not include the costs for other chemotherapies, hospital inpatient, and ICU care costs. Hospitals and clinics running the trials have experienced doctors and nurses that know how to handle this therapy. Expanding to new treatment arenas will be a challenge.

Research advances in combination trials targeting more than one pathway may increase response rates over single targeted agents. If a combination product is produced by one company, it could be priced more competitively than targeted agents developed and marketed through a competitors' alliance.

New approaches to adoptive T-cell therapies remain a hurdle, but the ultimate goals of increasing overall survival are not insurmountable. Changes in standards-of-care may limit access to patients for clinical trials for these new therapies.

Key Issues Addressed:

  • What adoptive T-cell (CAR-T & TCR) therapies are in development and for what indications?
  • What products and indications will be launched in the next 7 years?
  • Who is investing in the development of adoptive T-cell therapies, at what phase, and at what level of deal funding?
  • What are some of the cost implications for adoptive T-cell therapies, especially when combined with other immuno-oncology therapies?
  • What are the challenges to development and commercialization of adoptive T-cell therapies?
  • What challenges do payors face related to the high cost of specialty therapeutics?

Table of Contents

1. EXECUTIVE SUMMARY TO THE ADOPTIVE T-CELL THERAPEUTICS MARKET

  • Key Takeaway
  • Scope and Segmentation
  • Key Questions this Study will Answer
  • Executive Summary-Market Snapshot
  • Executive Summary-Market Snapshot (continued)
  • 8 Big Market Themes for Immuno-oncology Therapies
  • Hematological Cancers Dominate the Pipeline
  • Game Changing Companies
  • Investors Pour in Significant Funds
  • Key 2017 Predictions-Adoptive T-cell Therapy Market

2. DISRUPTIVE PIPELINE ANALYSIS

  • Key Methodology
  • Adoptive T-cell Therapy Drug Classes
  • Timeline of Adoptive T-cell Product Evolution
  • Timeline of Adoptive Immuno-oncology Product Approvals

3. COMPETITIVE LANDSCAPE

  • Competitive Landscape-Target Segments
  • Competitive Landscape-Target Product Counts
  • Adoptive T-cell Therapy Segmentation
  • Competitive Landscape-CAR-T (Chimeric Antigen Receptor T-cells)
  • Competitive Landscape-CAR-T (Chimeric Antigen Receptor T-cells) (continued)
  • Competitive Landscape-CAR-T (Chimeric Antigen Receptor T-cells) CR
  • Competitive Landscape-T-cell Receptor (TCR) Segment

4. PRODUCT DASHBOARDS OF LEADING ADOPTIVE T-CELL THERAPIES

  • CAR-T Product Dashboard
  • CAR-T Product Dashboard (continued)
  • TCR Product Dashboard

5. COMMERCIALIZATION ANALYSIS

  • Opportunities in this Market
  • Challenges for this Market
  • Potential Game Changing Immuno-oncology Therapies
  • Overall Environmental Impact Factors
  • Immuno-oncology Area Product Patent Expirations

6. COMMERCIALIZATION ANALYSIS-BIOMARKERS

  • Antigen Targets

7. COMMERCIALIZATION ANALYSIS-COST CONSIDERATIONS

  • Opportunities in this Market-Escalating Drug Costs
  • Adoptive T-cell Therapy Payor Environment
  • J-Codes, Annual Costs and US Payors
  • Adoptive T-cell Therapies-On-Label Reimbursement Path
  • Reimbursement Pathway-Off-Label: Medicare
  • Reimbursement Pathway-Off-Label: Commercial Payors
  • Reimbursement Pathway-Off-Label: Commercial Payors (continued)
  • A Snapshot of Global Drug Price Control Methods
  • Pitfalls to Avoid

8. COMMERCIALIZATION ANALYSIS-KEY COMPANIES AND PRODUCTS TO WATCH

  • Companies to Watch
  • Companies to Watch (continued)
  • Adoptive T-cell Therapy Forecast-2022 ($3.9 Billion) Forecasts by Product

9. COMMERCIALIZATION ANALYSIS-FUNDING CONSIDERATIONS

  • Immuno-oncology Milestones
  • Immuno-oncology Milestones (continued)
  • Deal and Financing-Adoptive T-cell Therapies
  • Deal and Financing-Adoptive T-cell Therapies (continued)
  • Deal and Financing-Adoptive T-cell Therapies (continued)
  • Deal and Financing-Adoptive T-cell Therapies (continued)
  • Deal and Financing-Adoptive T-cell Therapies (continued)
  • Deal and Financing-Adoptive T-cell Therapies (continued)
  • Deal and Financing-Adoptive T-cell Therapies (continued)
  • Deal and Financing-Adoptive T-cell Therapies (continued)
  • Deal and Financing-Adoptive T-cell Therapies (continued)
  • Deal and Financing-Adoptive T-cell Therapies (continued)
  • Deal and Financing-Adoptive T-cell Therapies (continued)
  • Deal and Financing-Adoptive T-cell Therapies (continued)
  • Deal and Financing-Adoptive T-cell Therapies (continued)
  • Deal and Financing-Adoptive T-cell Therapies (continued)
  • Deal and Financing-Adoptive T-cell Therapies (continued)
  • Deal and Financing-Adoptive T-cell Therapies (continued)
  • Deal and Financing-Adoptive T-cell Therapies (continued)

10. CONCLUSION AND FUTURE OUTLOOK

  • Key Conclusions
  • New Market Opportunities-Adoptive T-cell Therapies
  • The Last Word-3 Big Predictions
  • Legal Disclaimer

11. APPENDIX-CAR-T THERAPIES DEVELOPMENT PIPELINE SUMMARIES

  • Pipeline Analysis-CAR-T Segment, Products in Development
  • Pipeline Analysis-CAR-T Segment, Products in Development (continued)
  • Pipeline Analysis-CAR-T Segment, Products in Development (continued)
  • Pipeline Analysis-CAR-T Segment, Products in Development (continued)
  • Pipeline Analysis-CAR-T Segment, Products in Development (continued)
  • Pipeline Analysis-CAR-T Segment, Products in Development (continued)
  • Pipeline Analysis-CAR-T Segment, Products in Development (continued)
  • Pipeline Analysis-CAR-T Segment, Products in Development (continued)
  • Pipeline Analysis-CAR-T Segment, Products in Development (continued)
  • Pipeline Analysis-CAR-T Segment, Products in Development (continued)
  • Pipeline Analysis-CAR-T Segment, Products in Development (continued)
  • Pipeline Analysis-CAR-T Segment, Products in Development (continued)
  • Pipeline Analysis-CAR-T Segment, Products in Development (continued)
  • Pipeline Analysis-CAR-T Segment, Products in Development (continued)
  • Pipeline Analysis-CAR-T Segment, Products in Development (continued)
  • Pipeline Analysis-CAR-T Segment, Products in Development (continued)
  • Pipeline Analysis-CAR-T Segment, Products in Development (continued)
  • Pipeline Analysis-CAR-T Segment, Products in Development (continued)
  • Pipeline Analysis-CAR-T Segment, Products in Development (continued)
  • Pipeline Analysis-CAR-T Segment, Products in Development (continued)
  • Pipeline Analysis-CAR-T Segment, Products in Development (continued)

12. APPENDIX-T-CELL RECEPTOR THERAPIES: DEVELOPMENT PIPELINE SUMMARY

  • Pipeline Analysis-T-cell Receptor Segment, Products in Development
  • Pipeline Analysis-T-cell Receptor Segment, Products in Development (continued)
  • Pipeline Analysis-T-cell Receptor Segment, Products in Development (continued)
  • Pipeline Analysis-T-cell Receptor Segment, Products in Development (continued)
  • Pipeline Analysis-T-cell Receptor Segment, Products in Development (continued)
  • Pipeline Analysis-T-cell Receptor Segment, Products in Development (continued)
  • Pipeline Analysis-T-cell Receptor Segment, Products in Development (continued)
  • Pipeline Analysis-T-cell Receptor Segment, Products in Development (continued)
  • Pipeline Analysis-T-cell Receptor Segment, Products in Development (continued)
  • List of Exhibits
  • List of Exhibits (continued)
  • List of Exhibits (continued)
  • List of Exhibits (continued)

13. THE FROST & SULLIVAN STORY

  • The Frost & Sullivan Story
  • Value Proposition-Future of Your Company & Career
  • Global Perspective
  • Industry Convergence
  • 360° Research Perspective
  • Implementation Excellence
Back to Top